ELVN

46.5300.26%
HL

Helen Louise Collins

Chief Medical Officer

Dr. Helen Louise Collins, M.D. serves as Director of IO Biotech ApS since November 2023. She serves as Chief Medical Officer at Enliven Therapeutics, Inc. since the closing of the Merger on February 23, 2023 and was appointed in connection with the closing of the Merger. Dr. Collins served as Enliven’s Chief Medical Officer from July 2021 until the closing of the Merger. She serves as Independent Director at Kura Oncology, Inc. since July 28, 2021. She served as Independent Director at IO Biotech, Inc. since November 09, 2023 until March 31, 2026. She served as Executive Vice President from August 2019 and Chief Medical Officer from March 2017 to April 2021and served as its Senior Vice President from March 2017 to August 2019. Dr. Collins has oncology expertise, as well as clinical development and medical affairs experience. She joined Five Prime in June 2016 as Vice President of Clinical Development from June 2016 to March 2017and has been instrumental in leading the Five Prime’s clinical development programs. From June 2013 to June 2016, she held positions of increasing responsibility at Gilead Sciences, Inc. including Program and Clinical Lead for Gileads GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013, she held positions of increasing responsibility at Amgen Inc. including Global Lead of Oncology Biosimiliars. Prior to joining Amgen, she practiced as a Medical Oncologist and Hematologist for few years at Redwood Regional Medical Group (RRMG) and served as President of RRMG from 2006 to 2009. In 2005, she Co-Founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counties in the northern San Francisco Bay Area. Dr. Collins is Board certified in both Oncology and Internal Medicine. Dr. Collins completed her residency in internal medicine at Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where, she concentrated in gastrointestinal cancer. Dr. Collins received an BA in Chemistry from Bryn Mawr College and an M.D. from Johns Hopkins University School of Medicine.

Positions